Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Blood Advances|January 31, 2024
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphomaEsther H Nie, Yi-Jiun Su, John H Baird, et al.
Leukemia & Lymphoma|August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Lu Chen, Stacy Pak, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Transplantation and Cellular Therapy|January 12, 2026
Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-AnalysisArmin Ghobadi, Theodora Anagnostou, Jacques Azzi, et al.
Blood Cancer Discovery|December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeHrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Lancet (London, England)|July 12, 2024
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 studyMatthew J Frank, John H Baird, Anne Marijn Kramer, et al.
American Journal of Cancer Research|September 15, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysisLori A Leslie, John H Baird, Ian W Flinn, et al.
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Pageof 3